Key facts
- This page summarizes NOVARTIS PHARMA AG's Form 3 filing for PRECISION BIOSCIENCES INC (DTIL).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 27 Jun 2022, 16:38.
NOVARTIS PHARMA AG - 15 Jun 2022 Form 3 Insider Report for PRECISION BIOSCIENCES INC (DTIL)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- DTIL
- Reported as of
- 15 Jun 2022
- Net transaction value
- $0
- Reporting owner signature
- Novartis Pharma AG /s/ Christian Rehm, Authorized Signatory /s/ Lukas Foertsch, Authorized Signatory
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
NOVARTIS PHARMA AG filed Form 3 for PRECISION BIOSCIENCES INC (DTIL) on 27 Jun 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
DTIL
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 12,407,440
- Date
- 15 Jun 2022
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Novartis Pharma AG is the record holder of the securities reported herein. As the parent of Novartis Pharma AG, Novartis AG is the beneficial ownership of these securities.